🇺🇸 FDA
Patent

US 7776827

Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome

granted A61KA61K38/046A61P

Quick answer

US patent 7776827 (Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome) held by ImmuneRegen Biosciences, Inc. expires Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ImmuneRegen Biosciences, Inc.
Grant date
Tue Aug 17 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/046, A61P, A61P7/06